Analyst Price Targets — IMNN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 17, 2026 12:38 pm | — | Maxim Group | $10.00 | $3.18 | TheFly | Imunon initiated with a Buy at Maxim |
Latest News for IMNN
Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION 2 Strong enrollment demonstrates the confidence of principal investigators from prestigious cancer institutions in the trial design and its potential for a successful outcome Enrollment ahead of plan across all study…
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance with IMNN-001 vs. controlHighly favorable safety and tolerability profile Study, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001's unique mechanism…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMNN.
U.S. House Trading
No House trades found for IMNN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.